CST PathScan®抗体芯片试剂盒-试剂盒-抗体-生物在线
CST PathScan®抗体芯片试剂盒

CST PathScan®抗体芯片试剂盒

商家询价

产品名称: CST PathScan®抗体芯片试剂盒

英文名称: PathScan® EGFR Signaling Antibody Array Kit (Chemiluminescent Readout)

产品编号: 12622S

产品价格: null

产品产地: 美国

品牌商标: CST

更新时间: null

使用范围:

深圳市宇德立生物科技有限公司
  • 联系人 :
  • 地址 : 深圳市宝安区西乡宝民二路贤基大厦4E
  • 邮编 :
  • 所在区域 : 广东
  • 电话 : 133****4454
  • 传真 : 0755-26457513
  • 邮箱 : 1484332550@qq.com

 PathScan®抗体芯片试剂盒是一种基于玻片的ELISA检测方法,为在多种规格中研究关键信号通路节点的信号转导而设计。

每个试剂盒提供了两张玻片;每张玻片包含16个分析,每个分析中点了许多抗体。接下来使用检测抗体混合物来检测目标蛋白。每个分析中还包含了阳性和阴性对照。

试剂盒分为化学发光检测和荧光检测两种。化学发光检测适用于胶片,不需要使用其他仪器,而荧光值读数可以在荧光成像仪中获取。

试剂盒使用最高质量的抗体进行生产和优化,为您提供了最好的特异性和灵敏性。

试剂盒可以分析小体积裂解物中的多种蛋白,节省宝贵的时间和试剂。

化学发光检测是一种方便简单的检测方法,不需要专门的仪器。

技术支持由CST公司开发和生产这个产品并最了解它们的分子检测组提供。

12622     PathScan® EGFR Signaling Antibody Array Kit (Chemiluminescent Readout)

12785     PathScan® EGFR Signaling Antibody Array Kit (Fluorescent Readout)

12856     PathScan® Stress and Apoptosis Signaling Antibody Array Kit (Chemiluminescent Readout)

12923     PathScan® Stress and Apoptosis Signaling Antibody Array Kit (Fluorescent Readout)

13047     PathScan® Th1/Th2/Th17 Cytokine Antibody Array Kit (Chemiluminescent Readout)

13124     PathScan® Th1/Th2/Th17 Cytokine Antibody Array Kit (Fluorescent Readout)

13788     PathScan® Immune Cell Signaling Antibody Array Kit (Fluorescent Readout)

13792     PathScan® Immune Cell Signaling Antibody Array Kit (Chemiluminescent Readout)

14471     PathScan® Intracellular Signaling Membrane Array Kit (Chemiluminescent Readout)

14821     PathScan® Cancer Phenotype Antibody Array Kit (Chemiluminescent Readout)

14822     PathScan® Cancer Phenotype Antibody Array Kit (Fluorescent Readout)

7949       PathScan® RTK Signaling Antibody Array Kit (Fluorescent Readout)

7982       PathScan® RTK Signaling Antibody Array Kit (Chemiluminescent Readout)

9474       PathScan® Akt Signaling Antibody Array Kit (Chemiluminescent Readout)

 

9700       PathScan® Akt Signaling Antibody Array Kit (Fluorescent Readout)

Array Slides - EGFR Signaling Array Kit  2 ea          
Detection Ab Cocktail A(10X) - EGFR Signaling Array Kit 150 µl          
Detection Ab Cocktail B(10X) - EGFR Signaling Array Kit 150 µl          
16-Well Gasket 2 ea          
20X LumiGLO®Reagent and 20X Peroxide #7003 5 ml each          
HRP-Linked Streptavidin (10X) 300 µl          
Cell Lysis Buffer (10X) #9803 15 ml          
20X Array Wash Buffer 15 ml          
Sealing Tape 2 sheets          
Array Blocking Buffer 5 ml          
Chemiluminescent Development Folder 2          
Array Diluent Buffer 15 ml          

Specificity / Sensitivity

 

PathScan® EGFR Signaling Antibody Array Kit (Chemiluminescent Readout) detects the target proteins as specified on the Array Target Map. No substantial cross-reactivity has been observed between targets. This kit is optimized for cell lysates diluted to a total protein concentration between 0.2 and 1 mg/ml (see kit protocol). All capture antibodies have been validated for human and mouse-derived samples.

 

Description

 

The PathScan® EGFR Signaling Antibody Array Kit (Chemiluminescent Readout) uses glass slides as the planar surface and is based upon the sandwich immunoassay principle. The array kit allows for the simultaneous detection of phosphorylated EGFR, HER2, c-Met on distinct sites as well as a number of key signaling nodes found downstream of these receptor tyrosine kinases (RTKs). Target-specific capture antibodies have been spotted in duplicate onto nitrocellulose-coated glass slides. Each kit contains two slides allowing for the interrogation of 16 different samples. To improve assay performance the content of this array is split between two sub-arrays. The pads on left-hand side of each slide belong to sub-array A while the pads on the right-hand side of each slide belong to sub-array B. Cell lysates are incubated on the slide followed by a biotinylated detection antibody cocktail A or cocktail B (each cocktail for the corresponding sub-array). Streptavidin-conjugated HRP and LumiGLO® Reagent are then used to visualize the bound detection antibody by chemiluminescence. An image of the slide can be captured with either a digital imaging system or standard chemiluminescent film. The image can be analyzed visually or the spot intensities quantified using array analysis software.

 

 

Figure 1. Target map of the PathScan® EGFR Signaling Antibody Array Kit (Chemiluminescent Readout) #12622. † A reduction in a signal associated with E746-A750 deletion mutant was observed after treatment of cells with the small molecule inhibitors Gefitinib #4765 and Erlotinib #5083.

 

Figure 2. A-431 cells were grown to 90% confluency and then serum-starved overnight. Cells were stimulated with Human Epidermal Growth Factor (hEGF) #8916 (100 ng/ml, 5 min). Cell extracts were prepared and analyzed using the PathScan® EGFR Signaling Antibody Array Kit (Chemiluminescent Readout) #12622. Images were acquired by briefly exposing the slide to standard chemiluminescent film.

 

Figure 3. Calu-3 cells were grown to 90% confluency and then lyzed using a buffer containing (P) or devoid of (NP) phosphatase inhibitors. Cell extracts were prepared and analyzed using the PathScan® EGFR Signaling Antibody Array Kit (Chemiluminescent Readout) #12622. Images were acquired by briefly exposing the slide to standard chemiluminescent film.

 

Figure 4. HCC827 and H3255 are two non-small cell lung cancer (NSCLC) cell lines carrying two different gefitinib-sensitive mutants of EGFR: E746-A750 deletion in exon 19 and L858R point mutation, respectively. Cell extracts were prepared and analyzed using the PathScan® EGFR Signaling Antibody Array Kit (Chemiluminescent Readout) #12622. Images were acquired by briefly exposing the slide to standard chemiluminescent film.

Background

 

 

The Epidermal Growth Factor Receptor (EGFR) is a receptor tyrosine kinase (RTK) that constitutes an important disease driver, as well as a validated drug target. The potency of EGFR in driving tumorigenesis can be attributed to its pleiotropic intracellular signaling. Activated EGFR initiates a wide range of signaling modules and switches such as the Ras-Erk/MAP kinase, Akt, Src, Stat, and PKC. Two of the most common EGFR mutations occurring in lung cancer are the E746-A750 deletion and L858R point mutation. This array utilizes unique antibodies made by Cell Signaling Technology that are sensitive to each of these EGFR mutants, allowing specific target detection in cell extracts.

EGFR can interact and heterodimerize with other RTKs. HER2 (also known as ErbB2) is an oncogenic RTK belonging to the EGFR/HER family of RTKs and is an important heterodimerization partner of all HER family members. Another prominent heterodimerization partner of EGFR is c-Met. c-Met is an RTK serving as a receptor for the hepatocyte growth factor (HGF). c-Met can induce cell scattering, migration, and invasion. It has been shown that c-Met is responsible for some cases of tumor resistance to EGFR-targeted therapies and is a contributing factor to tumor metastasis.

PLCγ is a phosphoinositide-specific phospholipase. EGFR can activate PLCγ that, in turn, hydrolyzes phosphoinositide phospholipids residing within the inner leaflet of the plasma membrane. This hydrolysis generates two important second messengers: inositol 1,4,5-triphosphate (IP3) and diacylglycerol (DAG). IP3 causes calcium mobilization from intracellular storage pools, while DAG (together with calcium) activates PKC. MEK1 is a dual-specificity protein kinase and serves as the MAP kinase kinase for Erk1 and Erk2. Upon EGFR activation, MEK1 is phosphorylated by Raf and, in turn, phosphorylates the Erk kinases at Thr202 and Tyr204, leading to their activation. Activated Erk MAP kinase is a major signaling node with a multitude of substrates and primarily transmits growth and proliferation signals. Akt is another important protein kinase downstream of EGFR. Akt is activated by many RTKs and has a large number of intracellular substrates. Akt generates anabolic growth and survival signals. Stat3 is activated in response to EGFR stimulation, as well as in response to activation of a variety of cytokine receptors. Stat3 is a well-established oncogene that is also a transcription factor.

 

The oncogenic signals generated by activated EGFR are a focus of intense drug discovery efforts. It has become clear that in many cases a single agent inhibiting only one target is unable to cause tumor cell death in vivo. To monitor the blockade of EGFR signals alongside markers of cell death, cleaved PARP is included in this array. PARP is an enzyme involved in DNA repair. As a part of the apoptotic process, PARP is irreversibly inactivated by endoproteolytic cleavage executed by activated cell death proteases, such as caspase-3 and caspasae-7.

12785 PathScan® EGFR Signaling Antibody Array Kit (Fluorescent Readout)

12856 PathScan® Stress and Apoptosis Signaling Antibody Array Kit (Chemiluminescent Readout)

12923 PathScan® Stress and Apoptosis Signaling Antibody Array Kit (Fluorescent Readout)

13047 PathScan® Th1/Th2/Th17 Cytokine Antibody Array Kit (Chemiluminescent Readout)

13124 PathScan® Th1/Th2/Th17 Cytokine Antibody Array Kit (Fluorescent Readout)

7323 PathScan® Intracellular Signaling Array Kit (Chemiluminescent Readout)

7744 PathScan® Intracellular Signaling Array Kit (Fluorescent Readout)

7949 PathScan® RTK Signaling Antibody Array Kit (Fluorescent Readout)

7982 PathScan® RTK Signaling Antibody Array Kit (Chemiluminescent Readout)

9474 PathScan® Akt Signaling Antibody Array Kit (Chemiluminescent Readout)

 

9700 PathScan® Akt Signaling Antibody Array Kit (Fluorescent Readout)